R

Remix Therapeutics

Biotech firm developing mRNA-degrading therapies

Director Commercial Project Management & Launch Excellence

Program ManagementConfirmed live in the last 24 hours
Full-timeWatertown, MA, USAIn-person

About the Job

Requirements

  • A bachelor's degree in life sciences, business, or a related discipline, or equivalent relevant experience.
  • At least 10 years of relevant experience in biotechnology or pharmaceuticals, including substantial responsibility for commercial project management, launch readiness, or cross-functional program leadership.
  • Understand the sequence and dependencies of commercialization, including regulatory milestones, medical readiness, market access, patient services, field execution, distribution, supply, and commercial systems.
  • Apply integrated scheduling, critical path analysis, capacity planning, change control, scenario planning, and risk management; use tools such as Smartsheet, Microsoft Project, or comparable platforms to support execution.
  • Align senior stakeholders and functional experts without direct authority, resolve disagreements constructively, and secure clear commitments across competing priorities.
  • Demonstrated leadership of at least one product launch from prelaunch planning through commercialization, with direct responsibility for an integrated launch plan and governance.
  • Experience in a small or emerging biotechnology company, including building capabilities with lean teams, limited infrastructure, and external service providers.

Responsibilities

  • Build and maintain the integrated launch roadmap, defining workstreams, deliverables, accountable owners, milestones, interdependencies, and the critical path from prelaunch preparation through early commercialization.
  • Partner with leaders to translate launch objectives into functional plans, readiness criteria, resource requirements, and measurable outcomes; reconcile competing priorities and identify gaps between functional plans.
  • Establish fit-for-purpose launch governance, a cross-functional launch team, workstream meetings, decision rights, and escalation pathways.
  • Lead focused meetings with clear agendas, decisions, owners, and follow-up actions; maintain a decision log and ensure unresolved issues reach the appropriate decision-maker.
  • Provide concise leadership updates on readiness, critical dependencies, and decisions required; present options and tradeoffs with a recommended path forward.
  • Build productive relationships across internal teams and external partners; clarify expectations, resolve handoff gaps, and address capacity constraints before they affect launch readiness.
  • Implement practical project management standards, templates, dashboards, and a shared source of launch information, keeping processes proportional to the organization's size and needs.
  • Maintain an integrated register of risks, assumptions, issues, and dependencies; assign owners, evaluate potential impact, and track mitigation plans, contingency actions, and escalation triggers.
  • Assist in readiness reviews and launch simulations to test critical workflows, such as the path from prescription through coverage, dispensing, and patient support; confirm evidence of readiness and close identified gaps.

Desired Qualifications

  • Experience with a company's first commercial launch is strongly preferred.
  • Experience with oncology and/or rare disease therapies is preferred.

About the Company

Remix Therapeutics

Biotech firm developing mRNA-degrading therapies

Remix Therapeutics develops medicines for rare diseases by using targeted degradation of mRNA with an oral small molecule. Its lead candidate REM 422 degrades messenger RNA to stop production of disease-causing proteins and is in Phase 1 trials for ACC and AML, with FDA Orphan Drug designation. The company funds R&D through grants, partnerships, and eventual commercialization, leveraging collaborations with larger pharma. Its goal is to deliver safe and effective medicines for rare cancers and genetic disorders by advancing REM 422 and expanding its portfolio to address unmet medical needs.

Company size
51-200
Company stage
IPO
Headquarters
Cambridge, MA
Founded
2018

Recently Posted Jobs

Explore more opportunities at Remix Therapeutics

See more jobs